Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hello, Nice stock to own. They will be a $4 stock by mid summer.
This was a 2/24 news release...
Management has been focusing their efforts on their Northern Vine Lab buildout after receiving their controlled substance dealers license (“CSL”) in 2016. The lab setup has been expedited and is now approximately 45 days away from opening its doors to licensed producer and MMAR patient customers for cannabis testing and analytics. Issues surrounding quality control and massive cannabis product recalls from licensed producers by Health Canada have recently taken headlines in the press. Northern Vine Labs is strategically positioned in Langley, British Columbia and holds a considerable geographic advantage over their few competitors as the region has many MMAR growers looking to prove their products’ quality.
Northern Vine Labs has the necessary licenses and controls in place to legally possess and work with the raw herb (cannabis) and its active ingredients. The company will provide analytical R&D and quality control testing on a large variety of cannabis based products, screening for cannabinoids, terpenes, microbiological contaminants, pesticides and residual solvents. The license also allows Northern Vine to formulate new products for licensed producers in Canada.
NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use
Marketwired MarketwiredMarch 16, 2017
NEW YORK, NY--(Marketwired - Mar 16, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals ( CSE : IN ) ( OTCQB : IMLFF ), an NNW client that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
The publication, entitled, "Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth," discusses the rampant growth of the cannabis market and how a number of biotech companies are developing cannabinoid-based therapies to address unmet medical needs.
To view the full publication visit: https://www.networknewswire.com/biotech-innovations-drive-cannabinoid-based-pharmaceutical-market-growth/
"Topical delivery, targeting to treat diseases on a local (rather than systemic) basis, is a preferred approach for various cannabinoid therapies, especially those targeting skin conditions. Canada-based InMed Pharmaceuticals, Inc.'s (IMLFF) flagship product, INM-750, is a cannabinoid-based topical therapy for a rare skin condition called Epidermolysis Bullosa (EB). As of now, there is no cure for EB. INM-750 is the first treatment ever developed specifically for this disease that has the potential to accelerate wound healing and skin regeneration; alleviate several symptoms such as inflammation, itching and pain; and possibly reverse the course of the disease through the modulating of keratins in the skin. With a potential global market of $1 billion per year, the treatment is being developed for topical application so as to maximize efficacy while minimizing side effects."
InMed's pipeline is further discussed in the publication, alongside a look at several industry peers.
Testing labs are needed. This would have never happened if it were sent to
a lab. HC will make ANY LP send the product to the labs... It would benefit
the LP as any errors would be the labs responsibility.
Aphria has a recall because of mislabeled canister. This would not have happened if the product was tested at a lab. Bad news for Aphria good news for ATTBF. This is why Abattis and alike labs are needed.
What I read was that Aurora will do their own testing which I feel
will be a good decision but HC will want an independent lab to do the testing on a non basis playing field. HC has the final word on this and
all will be subjected to testing before any product hits the streets or
patients. ATTBF is located in Vancouver along with Aurora, Supreme and many others. Seems Vancouver is the hub for MJ of the Pacific Northwest.
This makes me smile.
Golden Leaf Holdings to Present at Upcoming Session of Viridian Cannabis Investment Summit in New York City
Marketwired MarketwiredMarch 15, 2017
Golden Leaf Holdings to Present at Upcoming Session of Viridian Cannabis Investment Summit in New York City
Viridian Cannabis Investment Series NYC - 3.31.17Click here for high-resolution version
More
TORONTO, ON--(Marketwired - March 15, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE:GLH) (GLH.CN) (CNSX:GLH) (GLDFF), a leading cannabis oil solutions company built around recognized brands, is pleased to announce it will present at the upcoming Viridian Cannabis Investment Summit taking place at the John Jay College of Criminal Justice in New York City on Friday, March 31, 2017.
Golden Leaf Holdings Chief Executive Officer Don Robinson will present at this event.
Entitled "Cultural Diversity in the Cannabis Industry", this private event will explore opportunities to bring cultural diversity into the cannabis industry by educating and inspiring a more diverse group of professionals to get involved. Cannabis legalization is continuing throughout the U.S. and the world, spearheading the growth of a multi-billion-dollar market. Yet, the industry in general lacks cultural diversity among its entrepreneurs, investors, and workforce.
Viridian's Cultural Diversity in Cannabis event will present industry-leading companies, executives, investors, and thought leaders from a variety of cultural backgrounds who will discuss why and how they entered the cannabis industry. Presentations and panel discussions will be followed by networking sessions so that all participants will have the opportunity to meet and engage.
Golden Leaf Holdings to Present at Upcoming Session of Viridian Cannabis Investment Summit in New York City
Marketwired MarketwiredMarch 15, 2017
Golden Leaf Holdings to Present at Upcoming Session of Viridian Cannabis Investment Summit in New York City
Viridian Cannabis Investment Series NYC - 3.31.17Click here for high-resolution version
More
TORONTO, ON--(Marketwired - March 15, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE:GLH) (GLH.CN) (CNSX:GLH) (GLDFF), a leading cannabis oil solutions company built around recognized brands, is pleased to announce it will present at the upcoming Viridian Cannabis Investment Summit taking place at the John Jay College of Criminal Justice in New York City on Friday, March 31, 2017.
Golden Leaf Holdings Chief Executive Officer Don Robinson will present at this event.
Entitled "Cultural Diversity in the Cannabis Industry", this private event will explore opportunities to bring cultural diversity into the cannabis industry by educating and inspiring a more diverse group of professionals to get involved. Cannabis legalization is continuing throughout the U.S. and the world, spearheading the growth of a multi-billion-dollar market. Yet, the industry in general lacks cultural diversity among its entrepreneurs, investors, and workforce.
Viridian's Cultural Diversity in Cannabis event will present industry-leading companies, executives, investors, and thought leaders from a variety of cultural backgrounds who will discuss why and how they entered the cannabis industry. Presentations and panel discussions will be followed by networking sessions so that all participants will have the opportunity to meet and engage.
Organigram Announces Issuance of Stock Options
Marketwired MarketwiredMarch 14, 2017
MONCTON, NEW BRUNSWICK--(Marketwired - Mar 14, 2017) - Organigram Holdings Inc. (TSX VENTURE:OGI)(OGRMF) ("Organigram" or the "Company") announces that it has issued an aggregate of 1,500,000 incentive stock options to Greg Engel, a director of the Company and the Company's Chief Executive Officer, at an exercise price of $2.36 per share.
In accordance with Mr. Engel's employment contract, (i) 266,666 of the Options shall vest on March 13, 2018; (ii) 266,667 of the Options shall vest on March 13, 2019; and (iii) 266,667 of the Options shall vest on March 13, 2020.
Additionally, 350,000 stock options shall vest upon the common shares of the Company trading at a price at or greater than $4.76/share; and, 350,000 stock options shall vest upon the common shares of the Company trading at a price at or greater than $7.14/share. In each instance, the common shares of the Company must trade at or greater than the price set forth above for a period of not less than 20 consecutive trading days.
All of the above-mentioned options have been granted pursuant to the Company's Stock Option Plan which has been previously approved by the Company's shareholders and the TSX Venture Exchange. In accordance with the Plan, all such options shall expire 10 years after issuance.
Golden Leaf Signs Binding Letter of Intent for Strategic Acquisition in Canada
Marketwired MarketwiredMarch 14, 2017
Golden Leaf Signs Binding Letter of Intent for Strategic Acquisition in Canada
Golden Leaf Holdings' Competitive Strategy
More
TORONTO, ON--(Marketwired - March 14, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE:GLH) (GLDFF), a leading cannabis oil solutions company built around recognized brands, is pleased to announce that the Company has signed a binding Letter of Intent (LOI) to acquire (the "Transaction") Canadian based Medical Marihuana Group Corporation ("MMGC").
Strategic Fit with GLH
MMGC represents a strategic acquisition for Golden Leaf and provides key benefits to the Company, including:
Access for the GLH brand platform into the rapidly expanding Canadian and international marketplaces;
An international footprint across North America with access to the global marketplace through Canada;
Allowance for GLH to participate in the Canadian marketplace which is anticipated to become fully legalized in 2018; and
Leverage for GLH's growing, extraction, refining, sales and marketing expertise to provide a competitive advantage and head start with cannabis oil and related products in the Canadian market.
Don Robinson, Golden Leaf's CEO, commented, "The acquisition of Medical Marihuana Group is an exciting opportunity for our company and our shareholders. GLH becomes one of the first global competitors to operate across North America and international markets through Canada. It opens up new market opportunities, particularly in Canada, and enables us to expand our brands and development of oils/edibles into the Canadian market. We are very pleased to begin to execute on our strategic acquisition program with this announcement."
Golden Leaf's Competitive Strategy
The chart shown in the attachment illustrates Golden Leaf's strategy to build a market leader in branded cannabis products that is backed by real science and a commitment to lowest cost manufacturing.
While GLH is currently executing this strategy on an organic basis, the Company and its board of directors believes that it can accelerate growth and market positioning through a strategic, targeted acquisition strategy. Among the acquisition targets that the Company will focus on are existing production/processing/distribution licenses in other states, proprietary oil extraction technologies, and existing leading brands. The strategic acquisition program is intended to drive financial and shareholder value by seeking acquisitions that build GLH's brand portfolio, expand its regional presence and/or add technology and intellectual property.
The Transaction
Pursuant to the Transaction, and subject to adjustment in certain circumstances, shareholders of MMGC will receive an aggregate of C$10 million of common shares of GLH on the closing date of the Transaction and contingent consideration of C$5 million of common shares of GLH in the event that certain gross sales targets of GLH branded products in the Canadian medical cannabis market are met within 18 months of marketing efforts commencing in Canada.
In connection with the Transaction, GLH will enter into a licensing agreement with MMGC in an effort to leverage MMGC's relationship in the Canadian medical cannabis market and expand GLH's branded products into Canada. The intention is to introduce the Golden brand to Canadian patients in Q2-Q3 2017.
Pursuant to the Transaction, GLH has also agreed to fund the construction and build out of MMGC's cultivation facility, all of MMGC's marketing efforts of GLH's branded products in Canada and the working capital needs of MMGC pending closing of the Transaction.
The Transaction is subject to certain conditions, including CSE and regulatory approval, and will be completed within 5 business days of MMGC receiving the cultivation license from Health Canada.
Medical Marihuana Group is a Canadian company that has received it's "license to build" approval and has filed an application for a cultivation license, which, subject to construction and build out of the cultivation facility, it anticipates receiving on or before Q1 2018. It's facility in Ontario has expansion capacity of over 50,000 square feet of grow/extraction space. MMGC will be positioned as a vertically integrated provider to the medical patient marketplace in Canada, focused on serving high value patients through the rehabilitation and legal personal injury networks.
Abattis Team Positions for Next Stage of Growth
Accesswire AccesswireMarch 13, 2017
VANCOUVER, BC / ACCESSWIRE / March 13, 2017 / Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the "Company" or "Abattis") is pleased to announce the addition of Jaclyn Thomson, PhD, to our senior management team at Northern Vine Labs, and the appointment of Rene David to the Abattis Board of Directors. As the construction and buildout of Northern Vine Labs continues, more key management hires and appointments will accompany this next stage of growth.
Jaclyn will join the team and will be responsible for lab operations and testing protocols, while ensuring all transactions involving controlled substances comply with appropriate regulations and standards.
Jaclyn obtained her BSc. at the University of Victoria, and her PhD. in Organometallic Chemistry from the University of British Columbia. She brings a wide breadth of experience to the Company involving her previous positions in Quality Assurance, Scientific and Regulatory Consultation and Research. Jaclyn has years of experience in lab operations and is credited with publishing a highly successful academic manuscript regarding the extensive worldwide problem of Ginko Biloba adulteration in the journal Phytomedicine. Management feels confident that Jaclyn will be a key leader in Northern Vine's efforts to test for licensed producers and patients under the ACMPR system.
"Her appointment is a critical component of our overall strategy to position Northern Vine as the leader in not only the testing of, but also the subsequent formulations and science behind the cannabis plant," says Rene David, CFO of Abattis. "Jaclyn's in-depth knowledge of GMP, as well as natural health products and Health Canada regulations, means Northern Vine will maintain consistency with its procedures and ensure safe and reliable results on every product tested."
The shift of Mr. David from day-to-day operations into a position of oversight signals the lengthy preparations the Company has made to harness and sustain a focused growth trajectory. As CFO of Abattis, Mr. David has gained tremendous experience in the medical cannabis industry through working with Abattis and has been instrumental in guiding the Company's strategic expansion.
Jim Irving, Director, welcomes Mr. David to the Board: "We are happy to have Rene join the Board. His experience as CFO and COO will provide us with valuable insight and practical solutions to move the Company forward in the dynamic legal cannabis and nutraceutical industries, in Canada and abroad."
Mr. David has over 20 years of experience in real estate development, finance, and business strategy. He started his career at Vancity, Canada's largest Credit Union, as a real estate developer and then went into investment banking in Western Canada. He later expanded his interests to include the resource, food and water industries, and assisting corporations who are dealing with the globalization of local resources. In his normal course of duties, Mr. David's responsibilities include internal financial controls and analysis, procurement and contracts management. His continuous review of operating and capital plans is geared towards improving the internal controls and financial best practices in order to deliver the highest value product and strong company values.
Mr. David noted, "Since receiving our Health Canada Dealers License in September of 2016, we have narrowed our focus on key pillars for future growth; testing and analytics and product sales into international markets through its wholly owned subsidiary, Vergence Bioceuticals. As we prepare Northern Vine Labs for the next stage of operations, I felt it was appropriate to transition to the position of director and open up the leadership program to a greater level. A lot of hard work has been completed and I am excited to see what the Abattis team will bring as the Company moves into a stage of growth."
Hunchback I'm aware of what country my stocks are in. The point being is that it's discouraging for the investors in the US. Most likely they will look into Canadian stocks.
Ebota12, you are incorrect. Lab testing has moved to the forefront of
this industry. Because of the situation with OrganiGram, Mettrum Canopy,
Aurora etc. Northern Vine will be a leader as they are already have their
license for this testing. I agree with GreenReality. Revenue be significant. There are presently only 17 labs able to do this type of work.
Northen Vine is one of them.
Jeff Sessions Just Spoke Candidly About Marijuana (And You Won't Like What He Said)
Attorney General Jeff Sessions could very well be the pot industry's biggest obstacle over the next four years.
Sean Williams (TMFUltraLong) Mar 12, 2017 at 7:12AM
Seemingly nothing can stop the momentum behind marijuana lately. As of the end of 2016, 28 states had legalized medical cannabis, and residents in eight states had authorized the sale of recreational, adult-use pot. By comparison, prior to 2012 there were no recreationally legal states, and prior to 1996, not a single state authorized physicians to prescribe marijuana for medicinal purposes.
The public's opinion of cannabis has also changed just as rapidly. Gallup's polling shows that just 25% of respondents approved of the idea of legalizing weed nationally in 1995, compared to 60% in 2016, an all-time high. Data from a more recent survey from the independent Quinnipiac University showed 59% support for nationwide legalization, as opposed to 36% opposition, and a remarkably high 93% approval for the legalization of medical marijuana, compared to just 6% opposition.
Marijuana being rolled into a joint.
IMAGE SOURCE: GETTY IMAGES.
Long story short, the American public wants to see marijuana's expansion continue in an orderly fashion at the state level, or in some cases have the federal government completely decriminalize and reschedule the substance.
Jeff Sessions' candid views on marijuana
However, with Attorney General Jeff Sessions at the helm, you can rest assured that marijuana's march over the next four years is going to be an uphill struggle.
While in the Senate, Sessions was regarded as perhaps the most ardent opponent of marijuana. During a drug hearing last April, Sessions was quoted as saying "good people don't smoke marijuana," to aptly sum up his views on the substance. Sessions also blamed higher marijuana-related traffic fatalities as a reason not to support pot, and pointed to the lax policies of the Obama administration for creating these problems.
A little over a week ago, Sessions was at it again, speaking before the National Association of Attorney's General. While you can watch the two-minute video of Sessions speaking to his peers, here are some of the keynotes of his talk:
Jeff Sessions speaking to a crowd.
IMAGE SOURCE: JEFF SESSIONS SENATE WEBPAGE.
"My view is that crime does follow drugs. In the 70s and 80s, we saw so many lives destroyed by drug abuse. And I think the drugs today are more powerful, they're more addictive, and they can destroy even more lives. Young people had their lives destroyed. I, as you know, am dubious about marijuana -- as states can pass whatever laws they choose. But, I'm not sure we're going to be a better, healthier nation if we have marijuana being sold at every corner grocery store. I just don't think that's going to be good for us. We'll have to work our way through that.
Marijuana is a cure for opiate abuse? Give me a break! This is the kind of argument that's been made out there to just -- almost a desperate attempt to defend the harmlessness of marijuana of even its benefits. I doubt that's true. Maybe science will prove I'm wrong. But at this point in time you and I have a responsibility to use our best judgment, that which we've learned over a period of years, and speak truth as best we can. My best view is that we don't need to be legalizing marijuana."
And there you have it folks -- Attorney General Jeff Sessions remains no fan of the cannabis industry or its expansion.
One thing Sessions may be wrong about
However, he may also be ignoring some telltale data that suggests marijuana is indeed making inroads in reducing deaths related to opioid overdoses.
A trio of authors in October 2014 published a report online in JAMA Internal Medicine that examined the rate of opioid overdose deaths between 1999 and 2010 in all 50 states. The point being to see whether or not opioid overdose death rates declined in states that had legalized medical cannabis. After adjusting for age and other factors, states with medical cannabis laws had a roughly 25% lower mean annual opioid overdose mortality rate than states without a medical marijuana law. What's more, the longer medical cannabis was legal, the stronger the impact on reducing opioid overdose deaths.
A doctor holding up a bag of marijuana and cannabis-infused pills.
IMAGE SOURCE: GETTY IMAGES.
A separate study published last year examined all prescriptions from Medicare Part D that were filled between 2010 and 2013 and found that states that had legalized medical cannabis had a reduction in the number of painkiller prescriptions filled. This not only was estimated to have saved $165 million in costs in 2013, but it's perceived to be a safer alternative to treating chronic pain. Previous data has shown that there have been no marijuana overdose-related deaths compared to the more than 15,000 people who die annually from prescription opioid overdoses.
In other words, medical marijuana does appear to offer an alternative to opioid painkillers in certain instances.
But, will it matter?
Unfortunately, even these studies may not matter to the Trump administration, which appears ready to take a much tougher stance on pot than the Obama administration ever did.
During his campaign, President Donald Trump pledged his support behind medical marijuana "100%," and suggested that recreational weed should remain an issue that's dealt with at the state level. In recent weeks, White House press secretary Sean Spicer has suggested otherwise.
Donald Trump flanked by VP Mike Pence and DHS Secretary John Kelly.
IMAGE SOURCE: U.S. DEPARTMENT OF HOMELAND SECURITY, FLICKR.
While Trump continues to believe that medical marijuana should be available to states that choose to make it an option for physicians to prescribe, Spicer indicated that the federal government could be tougher with the enforcement of recreational pot laws. At this time no one is exactly sure how encompassing the federal government will be with its enforcement, but it clearly has the industry, and investors, on edge.
Sessions' views on marijuana will only further complicate matters. Though he pledged to follow the president's guidelines on pot, Sessions clearly doesn't like marijuana, and it wouldn't be surprising to see his influence be projected on new federal-level enforcement of the recreational pot industry.
Marijuana's growth has been phenomenal up to this point, but it's possible that the industry may not be infallible after all. Investors should be waiting patiently on the sidelines until we get more clarity on the degree to which the Drug Enforcement Agency plans to enforce federal marijuana laws in the weeks and months that lie ahead.
Marijuana stocks are overhyped: 10 better buys for you now
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and marijuana stocks were noticeably absent! That's right -- they think these 10 stocks are better buys.
Click here to learn about these picks!
About to Sell Marijuana Stocks? Read This First
Ready to sell marijuana stocks because of worries about what's ahead? First, consider why you bought the stocks in the first place.
Keith Speights (TMFFishBiz) Mar 12, 2017 at 9:03AM
Is it time to dump marijuana stocks?
The Trump administration is threatening to crack down on federal marijuana law violations. Marijuana stocks are falling as a result.
It's possible that the great marijuana stock surge might be over. But before you sell any marijuana stocks, consider why you bought them in the first place. Here are three major reasons for buying -- and whether or not it makes sense to sell for each one.
Marijuana bud over money
IMAGE SOURCE: GETTY IMAGES.
1. Profit from increasing demand
Some investors might have bought marijuana stocks for the same reason some bought computer stocks in the 1980s. They sought to profit from increasing overall demand. The idea behind this thought is that a rising tide lifts all boats. More people will want to buy marijuana, therefore marijuana stock prices will go higher.
For the most part, this approach has worked over the last year or two. However, if the Trump administration succeeds in enforcing federal marijuana laws, demand for legal marijuana isn't going to grow nearly as quickly as it would otherwise. That could be a sufficient reason to sell many marijuana stocks. There are a couple of things to note on this point before selling, though.
First, the White House might not be successful. States like California and Colorado aren't going to raise the white flag of surrender. If the states get the courts to agree that their laws should supersede federal laws on this front, marijuana stocks will still go up.
Second, remember that the risk of increased federal enforcement only impacts U.S. stocks. Canopy Growth (NASDAQOTH:TWMJF), for example, operates in Canada rather than the U.S. The company already claims a market cap of roughly $1 billion. Canopy Growth's stock could go significantly higher if recreational marijuana is legalized by the Canadian government as expected.
2. Investing in a business that's better than the competition
The best approach to investing is to find a business that stands above its peers and is positioned for long-term growth. This concept works in marijuana stock investing just like it does in other industries. And there are no doubt some investors who bought marijuana stocks with this idea in mind.
You can make a pretty good case that Medical Marijuana, Inc. (NASDAQOTH:MJNA) meets this criteria for marijuana stocks. It was the first publicly traded marijuana stock in the U.S. Medical Marijuana markets a broad array of cannabis products. It owns a sizable stake in Axim Biotechnologies, one of only a handful of biotechs developing cannabinoid drugs.
There's another key distinction for Medical Marijuana: The company's products don't violate federal marijuana laws. That's because these products only use substances derived from cannabis that don't fall under the Controlled Substances Act.
Reduced demand due to a federal crackdown on marijuana laws, however, could still negatively impact Medical Marijuana's growth prospects. That's an important factor to consider in deciding whether or not to hold on to any marijuana stock.
Growth prospects are especially important to think through when a stock trades at a high valuation. Medical Marijuana's market cap, for example, is more than 30 times sales -- not earnings, because the company remains unprofitable. That's a sky-high valuation that could only be remotely justified if tremendous growth was in store.
3. Follow the crowd
The worst reason to buy a stock is because others are doing so. Has this been a driving factor for some to buy marijuana stocks in recent months? Probably so.
If this was the rationale that you used in buying marijuana stocks, the best thing to do is to evaluate the stock based on its own merits rather than what others think about it. Ask the tough questions. Does the company have a solid and sustainable business model? How might federal enforcement of marijuana laws impact growth prospects?
A business and its stock that don't hold up under close scrutiny shouldn't be kept. And that's true regardless of what the crowd is doing.
Marapharm Ventures Inc. "Marapharm" Provides Construction Updates for 13.6 Acres of Industrial Land and Buildings Located in Washington State and 7 Acres in Nevada
PR Newswire PR NewswireMarch 11, 2017
KELOWNA, British Columbia, March 11, 2017 /PRNewswire/ --
"Nevada: December 19, 2016 Marapharm announced an update of construction on the 7 acres of property we own in Las Vegas. Some of the items and dates given then had time changes but the end date of March 30th for the buildings to be erected at the present time is on target. Photos and a video from a few days ago are posted on the website under the Las Vegas Project tab. The buildings are on the ground and the ground is being prepared. The plan is still to be growing by the end of April. The planning for the buildout of the entire 360,000 square feet of buildings is underway. All cultivation inventories have been pre-sold." Linda Sampson, Marapharm CEO.
Washington: March 9, 2017 the Washington State LCB (Liquor Control Board) have approved the plans submitted for the construction and renovation of one of the buildings located on the 13.6 acres of land recently purchased. The approval is for the 30,000 square foot building and comes with the requirement for Marapharm to provide regular photo updates of the progress to the LCB. The county is now reviewing the capping of the fire sprinklers for approval as part of the overall process.
News Release Summary References, for Washington State:
February 27, 2017 Marapharm announced steps underway to construct / create a cannabis campus. February 12, 2017 Marapharm announced that its subsidiary Marapharm Washington, LLC "Washington WA" had entered into an agreement to purchase 13.6 acres of industrial, highway frontage property located a few minutes south of the Canadian border for $4.2 million US. The transaction closes February 28, 2017. Previously, on June 16, 2016, the Company announced that it had concluded a deal for a lease of a 30,000 square foot building and an option to purchase 13.6 acres of industrial property located in Whatcom County, Washington State. Further, on August 17, 2016, Marapharm announced that Marapharm WA had closed on the purchase of the assets of a 30,000 square foot operating tier 3 marijuana cultivation and processing facility, located in Washington State and on September 27, 2016 and November 1, 2016 provided updates with regard to the Washington operations. Marapharm has been making lease payments on the property and has chosen to act on the option to purchase the land.
If you try inform other people about this company and the opportunities
it's call spamming....Really? I consider it sharing the wealth.
Marapharm Ventures Inc. "Marapharm" Speaks to Trading Activity of March 8, 2017
PR Newswire PR NewswireMarch 8, 2017
KELOWNA, British Columbia, March 8, 2017 /PRNewswire/ --
(MRPHF) (MDM)
"Publicly traded marijuana companies shares took a dive in value Wednesday after the Canadian government on legalization cautioned that they will take it's time on the move into recreational use. Accordingly companies in the sector saw their market values plunge from about 15% to 30% with a combined market loss of close to a billion dollars. Our market cap decreased by close to $30 million but it did recover towards the end of the day. We want shareholders to understand that while we made application to Health Canada for a marijuana license this was more than 3 years ago and while we are hopeful it will be dealt with some day, our focus is on the United States market. We own 6 marijuana licenses in the state of Nevada alone and we own 2 buildings and 7 acres of land, all clear title. At the present time the legalization of marijuana in Canada has no impact or influence on our business operations whatsoever." Linda Sampson, Marapharm CEO.
ABOUT MARAPHARM VENTURES INC.
Aurora Sets the Standard for Cannabis Industry Product Testing Disclosure
CNW Group CNW GroupMarch 9, 2017
TSXV: ACB
VANCOUVER , March 9, 2017 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (ACB.V) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) is pleased to announce that it is introducing the cannabis industry's most comprehensive product testing disclosure process. Today, the Company completed the first step in a two-step process that will provide Aurora clients and the general public with access to a simplified Certificate of Analysis (CoA) for every cannabis product available for sale on the Company's menu. The purpose of the new protocol is to provide clients with secure knowledge that every Aurora product available for purchase has been certified by an independent third-party laboratory as having passed testing for the widest possible range of potential contaminants.
The new system, developed in partnership with Anandia Labs Inc. ("Anandia"), Canada's foremost cannabis genetics and testing laboratory, will provide a certification link for each product featured on Aurora's menu, both through the Company's website and through its one-of-a-kind mobile application. Clicking the link will take clients to a product-specific webpage, providing a simplified CoA indicating that the product in question has been analyzed with high accuracy for potency, and passed Anandia's rigorous testing procedures for the presence of contaminants. These important enhancements will be implemented in two steps. The first step, now complete, added these certifications to the Company's website www.auroramj.com. The second step, to be completed soon, will update Aurora's online shop to place a certification link beside the image of each product for sale.
"This initiative further extends Aurora's best-in-class Quality Assurance and testing protocols, and gives our clients additional certainty regarding the purity and safety of the cannabis we produce and sell," said Terry Booth , CEO. "From the founding of our Company, we have established and emphasized a strict culture of regulatory compliance. We have never used pesticides in our production, yet we have always tested all the products we sell for the presence of pesticides and other potential contaminants. It is imperative that patients have confidence in the safety of the products they consume, and in the integrity of the medical cannabis system. We believe our testing disclosure process will raise the bar for the entire sector, and offer a model for other companies to follow."
Aurora has used independent laboratories to test every lot of product ever sold to clients for microbial contamination, as well as any potential contamination by heavy metals and pesticides. In October, 2016, the Company enhanced its procedures further by shifting its testing to Anandia, which is able to test cannabis for the presence of the broadest array of substances of any independent commercial laboratory in Canada . Since that time, Anandia has tested and passed 45 lots of Aurora products.
"Aurora's initiative to provide access to quality control test results will help their clients select the appropriate medication and give them peace of mind that it does not contain pesticides or other contaminants," said Dr. Jonathan Page , President and CEO of Anandia Labs. "Our industry leading testing protocols analyze for the presence of 51 pesticides and plant growth regulators, as well as other contaminants such as bacteria and heavy metals. We fully support Aurora in their efforts to bring a new level of transparency to the medical cannabis industry."
About Aurora
The worst is over...Fantastic buying opportunity!!
The worst is over...Fantastic buying opportunity...
Well said Les.
InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex
Accesswire AccesswireMarch 2, 2017
VANCOUVER, BC / ACCESSWIRE / March 2, 2017 / InMed Pharmaceuticals, Inc. ("InMed") (CNSX: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced the filing of an international Patent Cooperation Treaty (PCT) application, an important component in providing intellectual and commercial protection for INM-750 as a cannabinoid-based topical therapy for Epidermolysis Bullosa Simplex (EBS).
Epidermolysis Bullosa (EB) is a group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears from friction or trauma. Internal organs and bodily systems can also be affected by EB. It results from a defect of anchoring between the dermis and epidermis caused most frequently by the dysfunction or absence of certain proteins, called keratins, in the skin. EB is an orphan disease with no known treatment and has a significant unmet medical need. INM-750 will be the first therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms.
It is well documented that cannabinoid compounds have unique anti-inflammatory, analgesic and wound healing promoting properties via several mechanisms, thus making them theoretically excellent candidates for use in alleviating some of the symptoms associated with EB. InMed's proprietary Bioinformatics Database Assessment Tool predicted a dual approach that may prove beneficial to patients: first, the ability of certain cannabinoids to play a role in addressing key disease hallmarks (wound healing, infection, pain, itch, inflammation) in all patients with EB; and second, the ability of some cannabinoids to regulate the expression of various keratins that might compensate for the dysfunctional keratins that cause Epidermolysis Bullosa Simplex (EBS). EBS accounts for the vast majority of EB patients. InMed conducted several in vitro and in vivo assays and the results of these studies form the basis of this PCT application.
The Patent Cooperation Treaty (PCT) is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member states. There are 151 member countries within the PCT worldwide, so near global patent coverage can be obtained through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, India, and many other countries. The original priority date for this filing was May 26, 2015, therefore coverage of any underlying patent claims would extend for 20 years until 2035 in the United States, and may be subject to patent term extensions that would enable years of additional protection.
"This is a significant milestone achieved by our scientific team's discovery and validation of a new cannabinoid therapy to treat a serious disease with high unmet medical need. We are looking forward to fully understanding the potential impact of INM-750 in helping the EB community," said Dr. Sazzad Hossain, Chief Scientific Officer of InMed Pharmaceuticals. "The pre-clinical data emerging on the use of cannabinoids for EB, as well as other disease targets in our drug development portfolio, continue to validate our discovery approach using our bioinformatics assessment tool. These drug/disease targeting predictions are then followed by relatively quick, inexpensive, yet highly informative confirmatory laboratory studies to validate the predictions of the database. This approach is proving to be an important means to shorten drug development timelines as well as significantly reduce development costs."
FYI: InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa
Nice find John.
Click on the FYI on posts #3058, 3059.
What system?
Nope they don't. He probably has 700,000 shares...Just sipping the nectar!
Trump is not a politician. His word will be over ruled.
By the way he looks like a clown when he smiles and when he is serious...lol. America was built on the idea of "WE The People".
The sky is not falling.
This is a great stock because it allows science to mgf all the
other the components in MJ. through boisys. It will take a few months
but once they succeed bingo. THC and CBD, are a given. Easy to extract.
The other 90% are though and costly. This is a winner in is field.
Your Welcome.It's my money too.
anytime.
You are correct Radly.
FYI
Crude Oil
54.43
+0.44 (+0.81%)
Aurora Announces Q2 2017 Results
CNW Group CNW GroupFebruary 27, 2017
TSXV:ACB
VANCOUVER , Feb. 27, 2017 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (ACB.V) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) today announced its financial and operational results for the quarter ended December 31, 2016 (Q2 2017).
Operational Highlights and Recent Developments
Revenues of $3.9 million , as compared to $0 (nil) for Q2 2016. Q2 2017 revenues reflect 26.5% sequential growth over Q1 2017. Current sales pace exceeds $1.5 million per month. The Company continues to execute well on all aspects of its growth strategy through the construction of a state-of-the-art 800,000 square foot production facility, as well as continued investments in technology, innovation, partnerships, customer service, and sales and marketing.
Financial and operational highlights Q2 2017
Q2 2017
Q1 2017
Change
Active registered patients at close of period1
12,200
8,200
48.8%
Grams sold
538,045
435,720
23.5%
Revenues
$3.9 M
$3.1 M
26.5%
Adjusted gross margin
$4.4 M
$0.1M
$4.3 M
Net loss
$2.7 M
$5.6 M
($2.9 M)
Working capital
$60.1 M
$23.2 M
$36.0 M
Investment in capital assets
$4.2 M
$0.6 M
$3.5 M
(1)
As of the date hereof, the Company has approximately 12,800 active registered patients
Developments subsequent to the quarter
Current sales pace exceeding $1.5 million per month
Achieved a seven-day sales record between February 2 and 8, 2017 , with more than 68 kilograms sold over that period.
Received Health Canada license to sell cannabis oils, enabling Aurora to participate in this rapidly growing, higher margin segment of the medical cannabis market.
Announced a bought deal private placement financing of $60 million with an over-allotment option to increase the offering to up to $75 million .
Construction of the 800,000 square foot Aurora Sky facility continues to progress well and on schedule, with completion anticipated for the second half of 2017.Contracts have been awarded for the general contractor, and engineering and architectural suppliers. Cut and fill has been completed on the first 500,000 square feet, while screw piles have been sunk for the first 300,000 square feet.
Construction of the 800,000 square foot Aurora Sky facility continues to progress well and on schedule, with completion anticipated for the second half of 2017.Contracts have been awarded for the general contractor, and engineering and architectural suppliers. Cut and fill has been completed on the first 500,000 square feet, while screw piles have been sunk for the first 300,000 square feet.
Raised $5.5 million from the exercise of warrants, options and compensation options.
Approximately $23 million in additional gross cash proceeds potentially available from the exercise of warrants, stock options and compensation options/warrants.
On January 16, 2017 , the Company initiated a voluntary recall of products purchased from another licensed producer for resale purposes, which the Company had found to contain a pesticide not currently registered for use on medical cannabis.
The licensed producer that had sold the recalled cannabis to Aurora has agreed to fully reimburse the Company as follows:
A cash payment in the amount of $384,835 , constituting a full refund for product returned, and
A credit in the amount of approximately $450,000 , fully covering Aurora's costs incurred via extension of purchase credits by Aurora to its affected clients.
A cash payment in the amount of $384,835 , constituting a full refund for product returned, and
A credit in the amount of approximately $450,000 , fully covering Aurora's costs incurred via extension of purchase credits by Aurora to its affected clients.
Signed a Memorandum of Understanding with Radient Technologies Inc. ("Radient") for the joint development and commercialization of superior and standardized cannabinoid extracts at high throughputs.
Invested in Radient by way of a $2,000,000 10% convertible debenture. Additionally, announced the intention to participate in Radient's private placement financing of up to $1,250,000 units at $0.45 per unit.
Management commentary
"The Aurora team continues to exceed its very aggressive strategic goals set out and approved by its board of directors," said Terry Booth , CEO. "We are serving our rapidly growing base of active registered patients with some of the best cannabis on the market, and we continue to enrich the customer experience with innovations such as our hugely popular mobile app. We are also building a truly exceptional new 800,000 square foot state-of-the-art production facility, which we believe differentiates us and positions us exceptionally well to capitalize on the numerous opportunities created both by the rapidly growing medical cannabis market and the adult consumer market, once legalization is implemented. Additionally, initiatives such as our collaboration with Radient Technologies Inc. to research and implement superior extraction techniques, are indicative of how Aurora continues to be at the forefront of development in the sector. With one of the strongest cash positions in the industry, we are extremely well capitalized to execute on all our strategic growth plans, including the construction of our new Aurora Sky facility."
Highlights Q2 2017
Commenced construction on Aurora Sky, an 800,000 square foot state-of-the-art hybrid greenhouse facility anticipated to produce, at full capacity, approximately 100,000 kg of cannabis per year. The new facility is located at the Edmonton International Airport, providing important strategic advantages, such as logistics, customs, bonded warehousing and industrial infrastructure. Management believes the new facility will contribute to significant savings in production costs on a per gram basis.
Achieved new sales milestones:
Sales pace for the quarter in excess of $1.2 million per month.
November 2016 was a record month, with product sales in excess of 200 kilograms and gross revenue in excess of $1.7 million ;
Sales pace for the quarter in excess of $1.2 million per month.
November 2016 was a record month, with product sales in excess of 200 kilograms and gross revenue in excess of $1.7 million ;
Commenced trading on the TSX-V
Significantly strengthened its balance sheet with up to $41.9 million in new financings as follows:
Generated approximately $16.9 million in additional gross cash proceeds from exercise of warrants, stock options and compensation options.
$25 million in completed brokered private placement of 8% unsecured convertible debentures.
Generated approximately $16.9 million in additional gross cash proceeds from exercise of warrants, stock options and compensation options.
$25 million in completed brokered private placement of 8% unsecured convertible debentures.
Industry leading innovation with first mobile app launched for purchase of legal cannabis:
To date downloaded by approximately 23,200 individuals, averaging 60 secure system logins per hour during business hours from registered Aurora patients; and
Since launch of the app, patient ordering by phone has been reduced by 50%.
To date downloaded by approximately 23,200 individuals, averaging 60 secure system logins per hour during business hours from registered Aurora patients; and
Since launch of the app, patient ordering by phone has been reduced by 50%.
Further strengthened board governance with the appointment of Michael Singer as Chairman of the board and the appointment of Joseph Del Moral and Barry Fishman as members of the board.
Appointed Cam Battley as Executive Vice President.
Financial review Q2 2017
A comprehensive discussion of Aurora's financials and operations are provided in the Company's Management Discussion & Analysis and Financial Statements filed with SEDAR and can be found on www.sedar.com.
Revenues
The Company sold 538,045 grams of cannabis during the period under review, up 23.5% from Q1 2017. Revenues of $3.9 million were generated, as compared to $nil for the same period in the prior year, and up 26%, or approximately $0.8 million , from Q1 2017, reflecting an increase in the average price per gram of product sold.
Aurora commenced selling medical cannabis products on January 5, 2016 . Revenues generated to date reflect what management believes is the fastest growth rate of active registered patients in the industry as the Company scales up to full production capacity at its existing facility in Mountain View County, Alberta.
Gross Margin
Gross margin was $4.4 million for the three months ended December 31, 2016 . During the prior period, the Company did not generate any revenue from operations as the Company had not commenced sales of medical cannabis. However, the Company had been building up its inventory and recorded a gain on the changes in fair value of its biological assets of $2.2 million .
General & Administrative Costs
General and administration costs increased by $0.8 million for the three months ended December 31, 2016 . The overall increase was largely attributable to legal fees in relation to financing activities and due diligence conducted during the quarter, as well as the completion of the acquisition of CanvasRx.
Sales & Marketing
Sales and marketing expenses for Q2 2017 increased by $2.1 million compared to the same period in the prior year, due primarily to the Company commencing its commercial operations and sales of medical cannabis January 2016 and generated expense related to the roll-out of its commercial initiatives.
Net Loss
The Company recorded a net loss of $2.7 million for the quarter, as compared to a $0.6 million net profit for the same period in the prior year and a $2.9 million improvement from a $5.6 million loss for Q1 2017. The net loss includes non-cash share based payments totaling $2.5 million . The net profit for the prior year's second quarter was attributable mainly to a $2.2 million unrealized gain on changes in fair value of biological assets. As compared to the prior year, the net loss recorded for the period under review was due predominantly to a $5.2 million (including share-based payments) increase in operational expenses, including aforementioned share-based payments.
Read More
FYI
InMed Receives over $1,350,000 From Warrant Exercise
PR Newswire PR NewswireFebruary 27, 2017
CSE: IN
OTCQB: IMLFF
VANCOUVER, Feb. 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), reported today that prior to their expiry on Friday, February 24, 2017 a total of 10,672,750 common share purchase warrants have been exercised at a price of $0.13 per common share. Proceeds from the exercise of these warrants totalled $1,387,458 and 10,672,750 common shares were issued from InMed's Treasury.
"We are grateful for this expression of confidence by our warrant holders. This infusion of capital further strengthens our balance sheet as we continue the execution of our business plan and corporate objectives for 2017" said Chris Bogart, SVP of Investor Relations.
No commissions or placement fees have been paid related to the funds received from this warrant exercise. Proceeds raised are for general corporate purposes.
FYI
Organigram Completes Investigation and Provides Update on Compensation Policy
Marketwired MarketwiredFebruary 27, 2017
MONCTON, NEW BRUNSWICK--(Marketwired - Feb 27, 2017) - Organigram Holdings Inc. (TSX VENTURE:OGI)(OGRMF) (the "Company") announces that it has completed the investigation related to a recent contamination issue which resulted in voluntary recalls of medical cannabis products produced by the Company.
Denis Arsenault, Organigram's Chief Executive Officer, oversaw an extensive investigation that ultimately resulted in inconclusive findings with no hard evidence leading to the source of the contamination discovered. However, as a result of the contamination issue, the company has instituted a series of new protocols to prevent a reoccurrence of any issue of this nature. "We are determined to never have this happen again," said Arsenault. "The inquiry was thorough and was undertaken with the full cooperation and assistance of Health Canada and outside experts."
Seven new company-wide initiatives have now been implemented. They are:
Effective since January 1, 2017, Organigram tests every product lot for pesticides before they are made available for sale;
All inputs from outside suppliers are now tested before they are used. Inputs include such things as seeds, growing medium, fertilizers, water, etc.;
The company has updated its Integrated Pest Management (IPM) operating procedures to include periodic live plant sampling for pesticide screening;
The company has developed a formal program for receiving, securing and testing critical inputs on a routine basis;
A new, comprehensive screening process is now in place to pre-qualify suppliers before they are approved to do business with Organigram;
The company has installed closed-circuit cameras in areas of its facility that were previously not required to be monitored;
The company has developed and instituted a new education and training regime for all employees.
Arsenault also announced changes to the Company's compensation plan for uninsured clients impacted by the recall. Organigram will now provide all clients without insurance coverage a full credit for their affected purchases. Details about this credit will be communicated directly to each client. The total value of these credits represents approximately $2.26M and will be reflected in the company's Q2 results scheduled for publication in April 2017.
"Since the January recall, testing of harvested crops has been more comprehensive and effective -- no trace of any contaminant has been detected," said Arsenault. "As well, the company is undergoing a recertification process with Ecocert, the organization that validates our organic standards. Ecocert suspended -- but did not remove -- our certification during the investigation, and has been fully supportive of our efforts to bring operations back to full compliance with the organization's standards," Arsenault continues.
The well-being and satisfaction of former, existing, and future clients remains a top priority of the Company. "We are working extremely hard to regain the faith and trust of our clients," he concluded.
why the sudden drop?
Whats going on Oats...name change i believe...